Type2 Diabetes Mellitus
Conditions
Brief summary
A clinical trial to evaluate the pharmacokinetic profiles and safety of CKD-383.
Detailed description
A phase 1 clinical trial to evaluate pharmacokinetics and safety in healthy adult after oral administration of CKD-383 and co-administration of CKD-501, D745, D150.
Interventions
QD, PO
DRUGCKD-383
QD, PO
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult volunteers aged between 19 and 55 years old. 2. Weight ≥ 55kg(men) or ≥50kg(women), 3. Calculated body mass index(BMI) of 18.5 to 27.0kg/m2 * Body Mass Index(BMI) = Weight(kg) / \[Height(m)\]2 4. Women must meet one of the criteria written in below: * Menopause (No menstruation for 2 years) * Sterilization (hysterectomy or Oophorectomy, Tubal ligation etc.) 5. Men agree to contraception and not to donate sperm during the participation of clinical trial. 6. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand of the detailed description of this clinical trial.
Exclusion criteria
1. Those who have a clinically significant disease or medical history of hepatic-biliary system issues, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Digestive system disorder, Endocrine system disorder, Cardiovascular disorder, Blood tumor and/or mental health problems. 2. Those who have signs and symptoms of clinically significant dehydration or who are vulnerable to dehydration by poor oral intake. 3. Those who receive intravenous administration of radioactive iodine contrast agents (for Urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) within 48hours before the first administration of investigational product. 4. Those who have severe urinary tract infection or have a past medical history of it. 5. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption. 6. Those who have past medical history of gastrointestinal disorder(Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of drug 7. Those who have history of hypersensitivity to active pharmaceutical ingredient(Lobeglitazone, Empagliflozin, Metformin) or additives. 8. Those who have the test results written in below: * AST/ALT \> 1.25 times higher than upper normal level * eGFR(estimated Glomerular Filtration Rate, which is calculated by MDRD) \< 60 mL/min/1.73m2 * positive or reactive test result of Hepatitis B & C, HIV, PRP * Under 5 min resting condition, systolic blood pressure \>150mmHg or \<90mmHg, Diastolic blood pressure \>100mmHg, or \<50mmHg 9. Those who have a drug abuse history within one year or positive reaction on urine drug screening test 10. Those who received following drugs, which may affect results of clinical trial and safety. Ethical-the-counter (ETC) drugs and herbal medicines within 14 days before the first administration of the investigational drug. Over-the-counter (OTC) drugs, health foods and vitamin preparations within 7 days before the first administration of the investigational product. 11. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month before the first administration of investigational product 12. Those who exceeding an alcohol and smoke consumption criteria or can't stop smoking, consuming alcohol and caffeine during hospitalization period (Criteria: Caffeine \> 5 cups/day, Alcohol \> 210 g/week, Smoke \> 10 cigarettes/day) 13. Those who took grapefruit before the first administration of investigational product or can't stop taking grapefruit during hospitalization period 14. Those who received investigational product by participating in other clinical trial within 6 months before the first administration of investigational product 15. Those who donated whole blood within 2 months or apheresis within 1 month 16. Those who received transfusion within 1 month 17. Those who are pregnant or breastfeeding 18. Those who are deemed inappropriate to participate in clinical trial by investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUClast of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | AUClast: Area under the concentration-time curve from time zero to the last measurable concetnration time |
| Cmax of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | Cmax: Maximum plasma concentration of the drug |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| T1/2 of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | T1/2: Terminal elimination half-life |
| AUCinf of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | AUCinf: Area under the concentration-time curve from zero up to infinity |
| CL/F of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | CL/F: Clearance |
| Vd/F of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | Vd/F: Volume of distribution |
| Tmax of CKD-383 | 0(pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48(hours) | Tmax: Time to maximum plasma concentration |
Countries
South Korea
Outcome results
None listed